about
Serological, pharmacological and electrophysiological tests for the diagnosis of myasthenia gravisElectrical impedance myography as a biomarker to assess ALS progression.Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16).Reply.A randomized controlled trial of methotrexate for patients with generalized myasthenia gravisSUNCT headaches after ipsilateral ophthalmic-distribution zosterInternational clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument.Myasthenia Gravis.Clinical profile of patients with myasthenia gravis followed at the University Hospital, Federal University of Minas Gerais.Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis.Current therapeutic strategies for patients with polyneuropathies secondary to inherited metabolic disorders.Neurosarcoidosis.The MG Composite: A valid and reliable outcome measure for myasthenia gravis.Chronic inflammatory demyelinating polyradiculoneuropathy.A step forward for stiff-person syndrome.Management of common neurologic conditions in sports.Myotonic dystrophy.Neuromuscular complications of cancer diagnosis and treatment.An update on the classification and treatment of vasculitic neuropathy.Novel myelin protein zero mutation (Arg36Trp) in a patient with acute onset painful neuropathy.An easy approach to evaluating peripheral neuropathy.Improvement with corticosteroids and azathioprine in GAD65-associated cerebellar ataxia.Peroneal neuropathy following successful bariatric surgery. Case report and review of the literature.Fatal encephalitis in a patient with refractory celiac disease presenting with myorhythmia and carpal spasm.Vasculitic neuropathies.The forecast for podcasts: sunny skies but not necessarily with clear visibility.Stiff-person syndrome.R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia.Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite.Construct and concurrent validation of the MG-QOL15 in the practice setting.Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.History of outcome measures for myasthenia gravis.Clinical applications of therapeutic apheresis.The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis.The evaluation of polyneuropathies.Neurologic indications for therapeutic plasma exchange: an update.
P50
Q24235860-C81F7CB4-1416-441C-ADDC-16214EB7020FQ24615680-32A97915-EE74-4155-BCDE-1B4E036F8F84Q30275061-BBB599D8-81F5-4F92-9F00-958CB1B89469Q30275698-91330C73-1A3F-4B5D-88B0-A0D7BF492E8BQ30276605-29366C7C-DFBE-4D00-9CC1-AE4CD314F699Q30276633-5A6370FF-BE79-4599-8022-809EB78F9811Q30276744-6F4388A6-D699-4C87-831D-704D1C699E0EQ30278029-33A36DD0-B458-4FF6-9C9B-456F89AC3B46Q30278471-139FA2FA-561A-402B-AECC-74F6CDB2F55CQ30279121-D6D95136-A115-493B-8F63-246E9A405E50Q30300131-7810BF52-0CBE-4AF0-916E-B6C5372ACC42Q30301300-AE518731-0BD0-46AC-872F-BFE1DBE46ED5Q30311005-32ADC4B5-598C-4CA2-8FE7-377F86F7B725Q30311140-5BFBCC53-F5B8-41BB-A583-E34E4C2A04DBQ30424639-6A3DB702-555E-42CE-B095-39F363E8AED8Q30433776-A275CBBC-AA26-466C-911E-2A41983A58EFQ30436582-21640267-E120-4D03-BFAB-7B1B6B3B1914Q30437334-5D79C64A-49AA-4932-BB58-5B588E970C53Q30437697-4CE841EB-004A-494C-A984-2997257D8044Q30437730-56249749-A6BA-44F3-880E-504DADD7CE4CQ30438726-77D3C6AD-E3F1-4D34-BBC7-37A3E3A9B5FCQ30440230-362154E6-3DEF-46F6-9BA5-867147DCD253Q30441766-B6F3A729-F678-4AE2-B3FA-42B9EE2932DFQ30441830-E6A7F15D-C285-4138-92FD-FD60D159AA1FQ30441910-CBF6A3C3-E19E-460D-81EC-4C9BB0280874Q30442619-100C5737-F5C1-416B-B068-6C7909304296Q30443043-0ABA8AC3-6AD3-4037-8A75-51C55E927AB7Q30443393-50BF7DBA-22EA-4D15-8A8E-16F35B7E2802Q30443411-1229D1C9-6ABF-40D9-8E33-71BA1A7D7ED4Q30445597-27BD8333-BC22-407A-A326-2EADA83291C0Q30446611-D35B846B-13A4-45BF-BA70-9168C97FD726Q30446613-6E0DE9B8-B75C-475D-8441-725DA28F8B83Q30447364-14A27748-1873-47AB-A161-AB34E68851A1Q30449550-01CB1511-C3ED-4A67-995C-2584EB46DE57Q30450641-73E06E2A-5E51-4C74-A07A-92EFB2624D9AQ30451209-6736B7DA-D7C4-46B1-9872-25CC2AD18C31Q30451700-DAE75DCC-6EB6-46AA-B679-6898B4D97C08Q30452295-4289AB7A-C5D7-4D48-8A3D-14321DEF05CEQ30452894-2C6B0860-60A6-47A2-BD84-098B20A6A604Q30454297-197DD1D7-838B-4DCB-83F8-01EE99CCC5B9
P50
description
neurologist
@en
name
Ted Michael Burns
@ast
Ted Michael Burns
@en
Ted Michael Burns
@es
Ted Michael Burns
@nl
type
label
Ted Michael Burns
@ast
Ted Michael Burns
@en
Ted Michael Burns
@es
Ted Michael Burns
@nl
altLabel
Burns T
@en
Burns T. M.
@en
Burns T.
@en
Burns TM
@en
Burns
@en
T Burns
@en
T M Burns
@en
T. Burns
@en
T. M. Burns
@en
Ted Burns
@en
prefLabel
Ted Michael Burns
@ast
Ted Michael Burns
@en
Ted Michael Burns
@es
Ted Michael Burns
@nl